Amlodipine/atorvastatin/valsartan

Drug Profile

Amlodipine/atorvastatin/valsartan

Alternative Names: Atorvastatin/amlodipine/valsartan; CJ 30061; Valsartan/atorvastatin/amlodipine

Latest Information Update: 16 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator CJ HealthCare
  • Class Amides; Antihyperlipidaemics; Antihypertensives; Branched-chain amino acids; Dihydropyridines; Fatty acids; Fluorobenzenes; Heptanoic acids; Pyrroles; Small molecules; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel antagonists; Cytochrome P 450 enzyme system inhibitors; HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Hyperlipidaemia; Hypertension

Most Recent Events

  • 16 Aug 2017 Chemical structure information added
  • 03 Aug 2017 Amlodipine/atorvastatin/valsartan is available for licensing in World as of 03 Aug 2017. http://www.cjp.co.kr
  • 03 Aug 2017 Phase-III clinical trials in Hyperlipidaemia in South Korea (PO) (CJ Healthcare pipeline, August 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top